Skip to content
10-Q

Quarterly Report

CNBX PHARMACEUTICALS INC. CNBX

0001683168-25-002511

← back to feed
Filed
Apr 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Apr 14, 2025 4.2M sh
Cash And Equivalents Q2 2025 · Feb 28, 2025 $45.68K
Cash And Equivalents Q2 2025 · Aug 31, 2024 $26.42K
Current Liabilities Q2 2025 · Feb 28, 2025 $2.62M
Current Liabilities Q2 2025 · Aug 31, 2024 $2.51M
Current Assets Q2 2025 · Feb 28, 2025 $50.66K
Current Assets Q2 2025 · Aug 31, 2024 $31.39K
Total Assets Q2 2025 · Feb 28, 2025 $50.66K
Total Assets Q2 2025 · Aug 31, 2024 $31.39K
Stockholders Equity Q2 2025 · Nov 30, 2024 −$2.51M
Stockholders Equity Q2 2025 · Feb 29, 2024 −$2.36M
Stockholders Equity Q2 2025 · Nov 30, 2023 −$2.09M
Stockholders Equity Q2 2025 · Aug 31, 2023 −$2.02M
Shares Diluted Q2 2025 · Feb 29, 2024 30.99M sh
Shares Diluted Q2 2025 · Feb 29, 2024 29.37M sh
Operating Cash Flow Q2 2025 · Feb 29, 2024 −$196.24K
Eps Diluted Q2 2025 · Feb 29, 2024 −$0.01
Eps Diluted Q2 2025 · Feb 29, 2024 −$0.02
Eps Basic Q2 2025 · Feb 29, 2024 −$0.01
Eps Basic Q2 2025 · Feb 29, 2024 −$0.02
Sga Expense Q2 2025 · Feb 29, 2024 $133.65K
Sga Expense Q2 2025 · Feb 29, 2024 $282.57K
Rd Expense Q2 2025 · Feb 29, 2024 $107.2K
Rd Expense Q2 2025 · Feb 29, 2024 $208.27K
Net Income Q2 2025 · Feb 29, 2024 −$325.46K
Net Income Q2 2025 · Feb 29, 2024 −$503.98K
Operating Income Q2 2025 · Feb 29, 2024 −$206.43K
Operating Income Q2 2025 · Feb 29, 2024 −$378.33K
Gross Profit Q2 2025 · Feb 29, 2024 $34.42K
Gross Profit Q2 2025 · Feb 29, 2024 $112.5K
Cost Of Revenue Q2 2025 · Feb 29, 2024 $6.22K
Cost Of Revenue Q2 2025 · Feb 29, 2024 $17.57K
Revenue Q2 2025 · Feb 29, 2024 $40.64K
Revenue Q2 2025 · Feb 29, 2024 $130.07K